Joint Symposium 5
Oncology & Theranostics Committee / European Society for Medical Oncology (ESMO)
Tuesday, September 12, 15:00 – 16.30

Session Title
Prostate Cancer Theranostics: Where do we go?

Chairpersons
Elena Castro (Malaga, Spain)
Dennis Vriens (Leiden, The Netherlands)

15:00 – 15:22 Elena Castro, Madrid, Spain: Biology and Treatment Landscape in advanced Prostate Cancer and unmet Medical Needs

15:23 – 15:45 Bernd Krause, Rostock, Germany: Potential combination partners for PSMA radioligand therapy

15:45 – 16:12 Bastiaan Privé, Rotterdam, Netherlands: Moving PSMA RLT to earlier lines

16:13 – 16:30 Valerie Fonteyne, Ghent, Belgium: The future role of radiotherapy of prostate cancer

Educational Objectives
1. Get an overview of the current state of the art in diagnosing and treating metastatic prostate cancer
2. Understand current concepts of treating metastatic prostate cancer based on its biological properties
3. Get an overview of the expected changes in prostate cancer theranostics in the coming years

Summary
In this session, the audience will be provided with an overview of the current state of the art for diagnosing and treating metastasized prostate cancer. Nuclear Medicine approaches will be discussed in the broad context of a multidisciplinary approach to prostate cancer theranostics. A focus of the session will also be the development of the field in the coming years and how tackling currently unmet needs are expected to change our approach to prostate cancer treatment.

Key Words
prostate cancer, metastases, oligometastatic disease, radioligand therapy, radiotherapy, PET/CT, PSMA, chemotherapy, castration resistant prostate cancer